世界の癌治療用キナーゼ阻害剤市場:Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など...市場調査レポートについてご紹介

【英文タイトル】Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Overview of the World Market for Those Medicines
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Anti-Cancer Kinase Inhibitors
2.1 What are Protein Kinases?
2.2 Protein Kinases in Oncology
2.3 Mechanisms for Kinase Inhibition
2.4 Glossary of Terms

3. Anti-Cancer Kinase Inhibitors: World Market 2014-2024
3.1 The Global Market for Anti-Cancer Kinase Inhibitors in 2013
3.1.1 Leading Anti-Cancer Kinase Inhibitors by Sales, 2013
3.1.2 Leading Companies in the Protein Kinase Inhibitor Market
3.2 World Protein Kinase Inhibitors for Oncology Market: Sales Forecast by Class, 2014-2024
3.2.1 Changing Market Shares by Segment 2014-2024
3.2.2 Leading Anti-Cancer Kinase Inhibitors Manufacturers, 2014-2024
3.3 Bcr-Abl Inhibitors Lead the Protein Kinase Inhibitors for Oncology Market in 2013
3.3.1 Bcr-Abl Kinase Inhibitors: Drivers and Restraints 2014-2024
3.4 Imbruvica and Other Novel Kinase Inhibitors Will Eventually Dominate the Market
3.4.1 Other Kinase Inhibitors: Drivers and Restraints, 2014-2024

4. Leading National and Regional Markets, 2014-2024
4.1 Regional Breakdown of the World Protein Kinase Inhibitors for Drugs Treating Cancer
4.2 World Protein Kinase Inhibitors for Oncology Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change Through to 2024?
4.3 The US Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.4 The US Market: Drivers and Restraints, 2014-2024
4.5 The EU Union Anti-Cancer Kinase Inhibitors Market Forecast, 2014-2024
4.5.1 EU Market: Drivers and Restraints
4.5.2 German Market Forecast, 2014-2024
4.5.3 French Market Forecast, 2014-2024
4.5.4 Italian Market Forecast, 2014-2024
4.5.5 UK Market Forecast, 2014-2024
4.5.6 Spanish Market Forecast, 2014-2024
4.6 The Japanese Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.7 Forecasting Anti-Cancer Kinase Inhibitor Markets in Developing Countries, 2014-2024
4.7.1 Chinese Market Forecast, 2014-2024
4.7.2 Brazilian Market Forecast, 2014-2024
4.7.3 Russian Market Forecast, 2014-2024
4.7.4 Indian Market Forecast, 2014-2024

5. Leading Anti-Cancer Kinase Inhibitors Products, 2014-2024
5.1 Brc-Abl Inhibitors – Managed Care for Chronic Myeloid Leukaemia
5.1.1 Gleevec (imatinib) – Novartis
5.1.1.1 Historic Sales Performance
5.1.1.2 Lifecycle Management, Generic Challenges and Tasigna
5.1.1.3 Gleevec Forecast, 2014-2024
5.1.2 Sprycel (dasatanib) – Bristol-Myers Squibb
5.1.2.1 Patents and Market Exclusivity
5.1.2.2 Historic Sales Performance
5.1.2.3 Sprycel Forecast, 2014-2024
5.1.3 Tasigna (nilotinib) – Novartis
5.1.3.1 Indications and Market Exclusivity
5.1.3.2 Historic Sales Performance
5.1.3.3 Tasigna Forecast, 2014-2024
5.1.4 Bosulif (bosutinib) – Pfizer
5.1.4.1 Bosulif Forecast, 2014-2024
5.1.5 Iclusig (ponatinib) – ARIAD Pharmaceuticals
5.1.5.1 Iclusig Forecast, 2014-2024
5.2 EGFR Inhibitors
5.2.1 Tarceva (erlotinib) – Roche/Astellas
5.2.1.1 Patent Litigation and Market Exclusivity
5.2.1.2 Historic Sales Performance, 2004-2012
5.2.1.3 Tarceva Forecast, 2014-2024
5.2.2 Iressa (gefitinib) – AstraZeneca
5.2.2.1 Historic Sales Performance, 2003-2012
5.2.2.2 Iressa Forecast, 2014-2024
5.2.3 Gilotrif (afatinib) – Boehringer Ingelheim
5.2.3.1 Gilotrif Forecast, 2014-2024
5.3 Angiogenesis Inhibitors
5.3.1 Nexavar (sorafenib) – Bayer/Onyx
5.3.1.1 Historic Sales Performance, 2006-2012
5.3.1.2 Nexavar Forecast, 2014-2024
5.3.2 Sutent (sunitinib) – Pfizer
5.3.2.1 Historic Sales Performance, 2006-2012
5.3.2.2 Sutent Forecast, 2014-2024
5.3.3 Votrient (pazopanib) – GSK
5.3.3.1 Historic Sales Performance, 2010-2012
5.3.3.2 Votrient Forecast, 2014-2024
5.3.4 Inlyta (axitinib) – Pfizer
5.3.4.1 Inlyta Forecast, 2014-2024
5.4 BRAF and MEK Inhibitors
5.4.1 Zelboraf (vemurafenib) – Roche/Daiichi Sankyo
5.4.1.1 Zelboraf Forecast, 2014-2024
5.4.2 Mekinist (trametinib) and Tafinlar (dabrafenib) – GSK
5.4.2.1 Mekinist Forecast, 2014-2024
5.4.2.2 Tafinlar Forecast, 2014-2024
5.5 mTOR Inhibitors
5.5.1 Afinitor (everolimus) – Novartis
5.5.1.1 Patents and Market Exclusivity
5.5.1.2 Historic Sales Performance
5.5.1.3 Afinitor Forecast, 2014-2024
5.5.2 Torisel (temsirolimus) – Pfizer
5.5.2.1 Torisel Forecast, 2014-2024
5.6 Other leading Anticancer Kinase Inhibitors
5.6.1 Imbruvica (ibrutinib) –J&J/Pharmacyclics
5.6.1.1 Imbruvica Forecast, 2014-2024
5.6.2 Jakafi (ruxolitinib) – Novartis/Incyte
5.6.2.1 Jakafi Forecast, 2014-2024
5.6.3 Xalkori (crizotinib) – Pfizer
5.6.3.1 Xalkori Forecast, 2014-2024
5.6.4 Cometriq (cabozantinib) – Exelixis
5.6.4.1 Cometriq Forecast, 2014-2024
5.6.5 Caprelsa (vandetanib) – AstraZeneca
5.6.5.1 Caprelsa Forecast, 2014-2024
5.6.6 Tykerb (lapatinib) – GSK
5.6.6.1 Historic Sales Performance, 2007-2012
5.6.6.2 Tykerb Forecast, 2014-2024
5.6.7 Stivarga (regorafenib) – Bayer
5.6.7.1 Stivarga Forecast, 2014-2024

6. Anti-Cancer Kinase Inhibitors: R&D Pipeline, 2014-2024
6.1 Cyclin-Dependent Kinase 4/6 Inhibitors in Development
6.1.1 Palbociclib – Pfizer
6.1.1.1 Palbociclib Forecast, 2014-2024
6.1.2 LEE-011 – Novartis
6.1.2.1 LEE-011 Forecast, 2014-2024
6.1.3 Bemaciclib (LY2835219) – Eli Lilly
6.1.3.1 Bemaciclib Forecast, 2014-2024
6.2 Anaplastic Lymphoma Kinase (ALK) Inhibitors In Development
6.2.1 Alectinib – Roche
6.2.1.1 Alectinib Forecast, 2014-2024
6.2.2 Ceritinib (LDK378) – Novartis
6.2.2.1 Ceritinib Forecast, 2014-2024
6.2.3 AP26113 – ARIAD
6.3 Bruton’s Tyrosine Kinase and PI3K Inhibitors in Development
6.3.1 Idelalisib – Gilead
6.3.1.1 Idelalisib Forecast, 2014-2024
6.3.2 RG7601 (ABT-199) – Roche/AbbVie
6.3.2.1 ABT-199 Sales Forecast, 2014-2024
6.3.3 IPI-145 – Infinity Pharmaceuticals
6.3.3.1 IPI-145 Forecast, 2014-2024
6.3.4 Buparlisib (BKM120) – Novartis
6.3.4.1 Buparlisib Forecast, 2014-2024
6.3.5 ONO-4059 – Ono Pharmaceuticals
6.3.6 Copanlisib (BAY 80-6946) – Bayer
6.3.7 Pictilisib (GDC-0941) – Roche
6.3.8 BEZ235 – Novartis
6.4 MEK and BRAF Inhibitors in Development
6.4.1 Cobimetinib (GDC-0973) – Roche
6.4.1.1 Cobimetinib Forecast, 2014-2024
6.4.2 Encorafenib (LGX818) – Novartis
6.4.3 Binimetinib (MEK162) – Novartis
6.4.4 Selumetinib (AZD 6244) – AstraZeneca
6.5 Other Kinase Inhibitors in Development
6.5.1 Volasertib – Boehringer Ingelheim
6.5.1.1 Volasertib Forecast, 2014-2024
6.5.2 Neratinib (PB272) – Puma Biotechnology
6.5.3 Tivantinib (ARQ197) – Daiichi Sankyo
6.5.4 Dovotinib (TKI258) – Novartis
6.5.5 Dacomitinib – Pfizer
6.5.6 CO-1686 – Clovis Oncology

7. Qualitative Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.1 SWOT Analysis of the Protein Kinase Inhibitors for Oncology Market
7.2 Strengths
7.2.1 Oral Dosage Preferred Over Injection
7.2.2 Stratifying Patients Offers Clinical and Commercial Benefits
7.2.3 Targeted Kinase Inhibitor are Generally Well Tolerated
7.2.4 A Strong Pipeline of Novel Inhibitors Will Drive Market Growth
7.3 Weaknesses
7.3.1 Small Molecule Kinase Inhibitors Will Experience Generic Competition
7.3.2 Competitor Biologics Offer Differentiated Mechanisms of Action
7.3.3 Monoclonal Antibodies are More Specific than Small Molecules
7.4 Opportunities
7.4.1 Novel Targets Identified Through Cancer Genomics
7.4.2 Combination Therapies Bring Additive Benefits
7.4.3 Commercial Success Leveraged by Clinical Benefit
7.5 Threats
7.5.1 Small Molecules Generics Are Easy to Produce
7.5.2 Individual Kinase Targets are Rapidly Becoming Crowded
7.6 STEP Analysis of the Protein Kinase Inhibitors for Oncology Market
7.7 Porter’s Five Forces Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.7.1 Rivalry Among Competitors
7.7.2 Threat of New Entrants
7.7.3 Power of Suppliers
7.7.4 Power of Buyers
7.7.5 Threat of Substitutes

8. Research Interview
8.1 Interview with Dr Lawrence Bloch, Chief Finance and Business Officer, Infinity Pharmaceuticals, United States
8.1.1 Positioning a Novel Therapeutic in Blood Cancer Indications
8.1.2 Combining Therapies Offers Significant Benefit to Patients
8.1.3 Potential in Rheumatoid Arthritis and Blood Cancers

9. Conclusions
9.1 The Global Anti-Cancer Kinase Inhibitors Market to 2024
9.1.1 A Robust Pipeline of Innovative Drugs Driving Market Growth
9.2 Leading National Markets for Anti-Cancer Kinase Inhibitors to 2024


【レポート販売概要】

■ タイトル:世界の癌治療用キナーゼ阻害剤市場:Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など
■ 英文:Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024
■ 発行日:2014年6月
■ 調査会社:visiongain
■ 商品コード:VISG409052
■ 調査対象地域:グローバル
  • 世界の医療パッケージング(包装)市場動向(2012-2016)
    TechNavio's analysts forecast the Healthcare Packaging market to grow at a CAGR of 7 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased use of disposable medical products. The Global Healthcare Packaging market has also been witnessing the increase in outsourcing of healthcare packaging. However, the sustainability concerns with plastic pa …
  • 世界のスマートウォッチ市場動向:Global Smartwatches Market 2014-2018
    TechNavio's analysts forecast the Global Smartwatches market to grow at a CAGR of 115.2 percent over the period 2014-2018. One of the key factors contributing to this market growth is the entrance of big vendors into the Global Smartwatches market. The Global Smartwatches market has also been witnessing an increase in R&D spending. However, the lack of proper technology standards could pose a chal …
  • Baytex Energy Corp.:石油・ガスの開発・生産動向及びコスト分析- Q2, 2013
    Baytex Energy Corp. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Baytex Energy Corp. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for …
  • スリーブラベルの世界市場:熱収縮型スリーブラベル、ストレッチラベル、ROSOラベル、RFスリーブラベル
    About Sleeve Label Labels are printed pieces of paper, films, polymers, or other materials affixed to a product, or imprinted on the package or the body of a product. They provide important information about the product as well as the manufacturer. There are many labels available in the market, such as pressure-sensitive, in-mold, and sleeve labels. Presently, sleeve labels hold a very minimal per …
  • 世界のチョコレート、ココア、砂糖菓子類市場(~2019)
    The expansion of the global chocolate, cocoa and sugar confectionery industry is forecast to reach 2.3% p.a. in the coming years. Between 2008 and 2014 the market increased with an average annual growth of 6.2%. Currently, chocolate bars, blocks and slabs account for 15.4% of the global demand while the remaining market share is divided between cocoa fat, oil and butter (12.2%), cocoa powder (5.9% …
  • オペレーショナルインテリジェンス(OI)の世界市場2017-2021
    About Operational IntelligenceOI is a real-time dynamic and business analytics solution that delivers greater visibility and insight into businesses. Organizations use it for real-time capabilities when they need to take any immediate action like stopping the business process or making changes to the traditional system. The OI solutions offer applications such as query analysis for better real-tim …
  • 2014年戦略提言:Hepatitis Markers診断検査市場
    The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, …
  • 世界の塗料市場2015
    A worldwide strategic overview of the paints and coatings market, including:Sales forecasts for major market segments.Sales forecasts for key geographic regions: Asia Pacific, Europe, North America, Latin America, Africa/Mideast.The report reviews the major U.S. and international regulatory, technological, economic, demographic, and social trends with potentially significant impact on the paints a …
  • 短波赤外検出装置の世界市場
    Short wave IR (SWIR) detectors are transducers that convert radiation of objects in the short wave infrared range to a measurable form. They are cooled detectors that give better performance. MCT technology is mainly used to manufacture short wave IR detectors. This research report categorizes the global SWIR detector market on the basis of material, application, and geography. Various materials u …
  • 世界のスーパーマーケット/ディスカウントストア市場2014-2019:市場動態、ネット通販動向、競争状況
    Summary The “Global Hypermarkets, Supermarkets and Hard-Discounters, 2014-2019” report, published by Conlumino, provides analysis of current and forecast market data for retail sales in different category groups in the hypermarkets, supermarkets and hard-discounters retail channel across the globe. In addition, it highlights the fastest growing markets for hypermarkets, supermarkets and hard-disco …
  • 世界の回路遮断器市場:低圧遮断器、中圧遮断器、高圧遮断器
    About Circuit Breaker market A circuit breaker is an electrical switch used to protect an electric circuit from short-circuiting and overloading. A circuit breaker detects overloading and automatically switches off power supply. Circuit breakers are preferred over fuses as fuses have to be replaced after each operation while a circuit breaker has to be just reset after each operation. TechNavio's …
  • ソフトウェア定義データセンター(SDDC)の世界市場2015-2020
    Companies are often held back by an inflexible and complex IT infrastructure that cannot keep up with the changing needs of business. These restraints result in slow deployment of critical applications and services, limited resources, poor operation management, and unpredictable system integration. Virtualised servers and desktops hold the key to more efficient IT management. Collaboration through …
  • ホブ盤の世界市場2017-2021
    About Gear Hobbing Machine The manufacturing process used to cut tooth type geometries is known as hobbing. Hobbing is an important industrial process for gear manufacturing. The process is carried out using a hobbing machine with two skew spindles, one of these spindles is mounted with the hob while the other is mounted with a blank workpiece. Hobbing machines or hobbers, as they are commonly kno …
  • 血友病A・血友病Bの組換え因子補充療法:世界の薬剤市場予測・分析
    PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy - Global Drug Forecast and Market Analysis to 2024 Summary Congenital hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels …
  • 超疎水性コーティングの世界市場分析:原材料別(カーボンナノチューブ、シリカナノ粒子、グラフェン)、特性別(抗菌、防汚/濡れ、防食)、エンドユーザー別(電気・電子、輸送・アライド・ロジスティクス、医療、光学、建設、テキスタイル・レザー)、セグメント予測
    The global Superhydrophobic Coating Market is expected to reach USD 11.2 million by 2024, according to a new report by Grand View Research, Inc. Depleting freshwater reserves are one of the key concerns driving the demand for self-cleaning technologies. Superhydrophobics are completely water-repellent, fostering dirt to slide off from their surface at even slight elevation angles, which makes them …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。